Products for Research Use Only
RegisterLogin

Bulevirtide

CAT: 0804-HY-P3465-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P3465-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research[1][2].
CAS Number
2012558-47-1
Product Name Alternative
Myrcludex B
UNSPSC
12352209
Target
HBV
Type
Peptides
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/bulevirtide.html
Purity
99.70
Solubility
DMSO : 50 mg/mL (ultrasonic) |H2O : 83.33 mg/mL (ultrasonic; adjust pH to 8 with NH3·H2O)
Smiles
O=C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](C(C)C)C(N1[C@@H](CCC1)C(N[C@@H](CC(N)=O)C(N2[C@@H](CCC2)C(N[C@@H](CC(C)C)C(NCC(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CC4=CC=CC=C4)C(N5[C@@H](CCC5)C(N[C@@H](CC(O)=O)C(N[C@@H](CC6=CNC=N6)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N7[C@@H](CCC7)C(N[C@@H](C)C(N[C@@H](CC8=CC=CC=C8)C(NCC(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(N)=O)C(N9[C@@H](CCC9)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%10=CNC%11=CC=CC=C%10%11)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%12=CC=CC=C%12)C(N[C@@H](CC(N)=O)C(N%13[C@@H](CCC%13)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(O)=O)C(N[C@@H](CC%14=CNC=N%14)C(N[C@@H](CC%15=CNC%16=CC=CC=C%15%16)C(N%17[C@@H](CCC%17)C(N[C@@H](CCC(O)=O)C(N[C@@H](C)C(N[C@@H](CC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](C(C)C)C(NCC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CNC(CCCCCCCCCCCCC)=O
Molecular Formula
C248H355N65O72
Molecular Weight
5398.86
References & Citations
[1]Masetti C, et al. Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction. Liver Int. 2021 Jul;41 (7) :1441-1442.|[2]Cheng D, et al. Clinical effects of NTCP-inhibitor myrcludex B. J Viral Hepat. 2021 Jun;28 (6) :852-858.|[3]Donkers JM, et al., Mechanistic insights into the inhibition of NTCP by myrcludex B. JHEP Rep. 2019 Aug 1;1 (4) :278-285.|[4]Volz T, et al., The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013 May;58 (5) :861-7.|[5]Zhao K, et al., Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B. Emerg Microbes Infect. 2018 Nov 21;7 (1) :186.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Scientific Category
Peptides
Clinical Information
Launched

Alternative Products

CatalogName
BA1813-1Bulevirtide
A22756-10Bulevirtide 10mg
A22756-5Bulevirtide 5mg
GTR18919177-01Bulevirtide acetate
A22756-1Bulevirtide 1mg
A22756-25Bulevirtide 25mg
MBS5784861Bulevirtide (Myrcludex B)
MBS5784862Bulevirtide (Myrcludex B) acetate

Popular Products